Blog

iTeos Therapeutics closes an impressive $125M fundraising and recruits in Belgium with PaHRtners

iTeos Therapeutics closes an impressive $125M fundraising and recruits in Belgium with PaHRtners

iTeos Therapeutics is a clinical-stage biotech company specialised in the development of innovative immunotherapies. Having closed a Serie B2 financing of $125M, iTeos Therapeutics collaborates with PaHRtners to hire new profiles in Belgium.

Bright future at iTeos Therapeutics

To date, this is the largest fundraising event in the history of Life Sciences in Wallonia, which rises iTeos Therapeutics to the rank of a world-class player in immuno-oncology.

Proceeds from the $125M fundraising will further support the growth of the biotech and advance the clinical development of its two lead product candidates.

“We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership.” says Michel Detheux, CEO.

Two highly promising programs to improve life of cancer patients

Headquartered in Cambridge (USA) with a world-class research center in Gosselies, Belgium, iTeos Therapeutics is dedicated to extending and improving the life of cancer patients by developing novel cancer immunotherapies. Its two lead product candidates are a best-in-class adenosine A2A receptor antagonist and an ADCC-enabled antagonist anti-TIGIT antibody.

iTeos’ investigational A2A receptor antagonist, is expected to be complementary to a variety of immune-oncology approaches. This product candidate is being evaluated in a Phase 1/2 clinical trial, in partnership with Merck & Co. It has been designed to not cross the blood-brain barrier and demonstrates superior pharmacodynamics for complete target coverage.

The ADCC-enabled antagonist anti-TIGIT antibody developed by iTeos Therapeutics concerns the recognition and adhesion of immune cells to tumor cells. TIGIT entered a Phase I clinical trial in last February. It demonstrates great potential and could soon become one of the most desired programs by the pharmaceutical industry.

Ready to join this innovative biotech company?

“Here at iTeos, our professionals have the passion, knowledge and experience to make a difference. We are on a journey to develop life-saving medicine. To this end, iTeos collaborates with PaHRtners to hire new highly skilled profiles in Belgium” says Philippe Brantegem, VP Human Resources.

Want to be part of this project? Check out open positions at iTeos Therapeutics!

 

Director of Regulatory Affairs

Job description Apply

 

Senior Scientist – Translational Medicine in immuno-oncology

Job description Apply

 

Clinical Scientist

Job description Apply

 

Administrative Assistant, Clinical & Pre-clinical Team

Job description Apply

 

Medical writer

Job description Apply

Share